title: Long-term cardiac follow-up in survivors of a malignant bone tumour.
abstract: BACKGROUND
  Longitudinal studies of cardiac function in long-term childhood cancer survivors are scarce and frequently concern a median follow-up shorter than 13 years.
  
  
  METHODS
  Cardiac assessment was performed in 22 doxorubicin-treated long-term survivors of a malignant bone tumour at median 22 years (range 15-27.5) post-treatment. Age at follow-up was 39 years (range 27-59) and cumulative dose of doxorubicin was 360 mg/m(2) (range 225-550). Cardiac function was assessed by echocardiography and (24-h) ECG. The results were compared with those of earlier assessments at 9 years (1992) and 14 years (1997) post-treatment.
  
  
  RESULTS
  Systolic dysfunction was found in 27% (9% in 1997; P = 0.02) and diastolic dysfunction in 45% (18% in 1997; P = 0.02). Heart rate variability showed further deterioration compared with earlier results.
  
  
  CONCLUSIONS
  Twenty-two years after doxorubicin-treatment, bone tumour survivors showed progressive cardiac dysfunction.
authors.affiliation: Subdivision Paediatric Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. c.a.j.brouwer@bkk.umcg.nl
authors.forename: C A J
authors.initials: CA
authors.lastname: Brouwer
authors.forename: J A
authors.initials: JA
authors.lastname: Gietema
authors.forename: M P
authors.initials: MP
authors.lastname: van den Berg
authors.forename: M T E
authors.initials: MT
authors.lastname: Bink-Boelkens
authors.forename: N J
authors.initials: NJ
authors.lastname: Elzenga
authors.forename: J
authors.initials: J
authors.lastname: Haaksma
authors.forename: W A
authors.initials: WA
authors.lastname: Kamps
authors.forename: J M
authors.initials: JM
authors.lastname: Vonk
authors.forename: E G E
authors.initials: EG
authors.lastname: de Vries
authors.forename: A
authors.initials: A
authors.lastname: Postma
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001794:Blood Pressure / Q000502:physiology; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D002648:Child; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced* / Q000209:etiology; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D012516:Osteosarcoma / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D017741:Survivors; D013995:Time
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin